Publication:
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Simple item page
dc.bibliographiccitation.firstpage288
dc.bibliographiccitation.issue3
dc.bibliographiccitation.journalAnnals of Oncology
dc.bibliographiccitation.lastpage298
dc.bibliographiccitation.volume33
dc.contributor.authorHorwitz, S.
dc.contributor.authorO’Connor, O.A.
dc.contributor.authorPro, B.
dc.contributor.authorTrümper, L.
dc.contributor.authorIyer, S.
dc.contributor.authorAdvani, R.
dc.contributor.authorBartlett, N.L.
dc.contributor.authorChristensen, J.H.
dc.contributor.authorMorschhauser, F.
dc.contributor.authorDomingo-Domenech, E.
dc.contributor.authorIllidge, T.
dc.date.accessioned2022-04-01T10:01:00Z
dc.date.available2022-04-01T10:01:00Z
dc.date.issued2022
dc.identifier.doi10.1016/j.annonc.2021.12.002
dc.identifier.piiS0923753421048754
dc.identifier.urihttps://resolver.sub.uni-goettingen.de/purl?gro-2/105575
dc.language.isoen
dc.notes.internDOI-Import GROB-530
dc.relation.issn0923-7534
dc.rights.urihttps://www.elsevier.com/tdm/userlicense/1.0/
dc.titleThe ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
dc.typejournal_article
dc.type.internalPublicationyes
dspace.entity.typePublication

Files

Collections

Publications